Amsphere A3 Logo RGB 2021NOV23

Amsphere™ A3 is a next generation Protein A chromatography resin for advanced protein separation in downstream processing of therapeutic antibodies manufacturing.

 

Current A3 Programs 

0

Phase I

0

Phase II

0

Phase III

Commercial Programs  1

How Can Amsphere™ A3 Help Me?

Besides an outstanding high capacity, Amsphere™ A3 has an overall improved process robustness, flow characteristics, optimized impurity removal, productivity and resin lifetime.

JSR Life Sciences Amsphere Bead with Antibodies

 

Protein A Ligand
High DBC via controlled conformation and orientation
High alkaline stability from protein engineering
Surface modification
Low HCP levels by surface hydrophilization
Base bead formulation
High DBC at high flow rate
Good pressure and flow properties via rigid crosslinking

 

Catalog Numbers & Product Sizes

  • North America, EMEA & APAC Regions

    Amsphere-A3-Ordering-Information-2021JUN8-Global-pdf


    Download Ordering Info

Why use Amsphere™ A3?


 

Why Amsphere A3 is an Outstanding Choice for Antibody Fragment & FC-Fusion Purification

Universal Affinity Resin for
Non-classical mAbs

Simplify Your Supply Chain
& Minimize Costs

Excellent
Impurity Clearance

Learn More

OnDemand Webinar

Development of Protein A Continuous Chromatography


We are excited to have a speaker from our affiliate company, KBI Biopharma, a global CDMO, present on the development of Protein A continuous Chromatography.

Multicolumn continuous chromatography (MCC) is an emerging technology that can significantly reduce material costs and time in plant. This mode of chromatography can lead to shorter processing times and improve efficiency as well as productivity compared to a traditional batch process. Implementation of a fully integrated end-to-end continuous process has been limited due to the complexity and scalability of the process.

This presentation will focus on the conversion of a batch ProA step using Amsphere A3 resin to a 4-column continuous process on a BioSMB system. We evaluated the number of columns and resin volume needed to achieve balanced savings between resin/buffer usage and processing time when scaling up the
process across a range of feed titers.

Watch Now

Untitled design (36)
Presenter: Geok-Yong Yow Ph.D.
Scientist, KBI Biopharma Inc.

KBI Logo White

 

Featured Resources

Get a Quote

Ready to get a quote? Need more information?
Reach out to our team and let us know what information you need.
We are ready to help with pricing and more details.